Table of contents

Article

• Signal transduction by tumour necrosis factor and tumour necrosis factor related ligands and their receptors (1 November, 1999)

  Bryant G Darnay, Bharat B Aggarwal
• DAP kinase and DAP-3: novel positive mediators of apoptosis (1 November, 1999)

  Adi Kimchi
• Tumour necrosis factor gene polymorphisms as severity markers in rheumatoid arthritis (1 November, 1999)

  Cornelis L Verweij
• The rationale for the current boom in anti-TNFα treatment. Is there an effective means to define therapeutic targets for drugs that provide all the benefits of anti-TNFα and minimise hazards? (1 November, 1999)

  Marc Feldmann, Jan Bondeson, Fionula M Brennan, Brian M J Foxwell, Ravinder N Maini
• The function of tumour necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease (1 November, 1999)

  George Kollias, Eleni Douni, George Kassiotis, Dimitris Kontoyiannis
• Role of tumour necrosis factor α in experimental arthritis: separate activity of interleukin 1β in chronicity and cartilage destruction (1 November, 1999)

  Wim B van den Berg, Leo A B Joosten, George Kollias, Fons A J van de Loo
• Tumour necrosis factor and other cytokines in murine lupus (1 November, 1999)

  Argyrios N Theofilopoulos, Brian R Lawson
• Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis (1 November, 1999)

  R N Maini, P C Taylor, E Paleolog, P Charles, S Ballara, F M Brennan, M Feldmann
• Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNFα treatment (1 November, 1999)

  Gregory Harriman, Lesley K Harper, Thomas F Schaible
• Etanercept: therapeutic use in patients with rheumatoid arthritis (1 November, 1999)

  Leslie Garrison, Neil D McDonnell
• Preliminary results of early clinical trials with the fully human anti-TNFα monoclonal antibody D2E7 (1 November, 1999)

  Joachim Kempeni
• PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases (1 November, 1999)

  Carl K Edwards
• Pharmacoeconomic evaluation of new treatments: efficacy versus effectiveness studies? (1 November, 1999)

  C Bombardier, A Maetzel
• Safety, cost and effectiveness issues with disease modifying anti-rheumatic drugs in rheumatoid arthritis (1 November, 1999)

  James F Fries
• FDA perspective on anti-TNF treatments (1 November, 1999)

  William D Schwieterman
• European regulatory aspects on new medicines targeted at treatment of rheumatoid arthritis (1 November, 1999)

  Gottfried Kreutz
• Treatment of rheumatoid arthritis with interleukin 1 receptor antagonist (1 November, 1999)

  Barry Bresnihan
• Interleukin 10 treatment for rheumatoid arthritis (1 November, 1999)

  E William St Clair
• Clinical implications of tumour necrosis factor α antagonism in patients with congestive heart failure (1 November, 1999)

  Guillermo Torre-Amione, Sonny S Stetson, John A Farmer
• Immunomodulation by thalidomide and thalidomide analogues (1 November, 1999)

  Laura G Corral, Gilla Kaplan
• Anti-TNF antibody treatment of Crohn's disease (1 November, 1999)

  S J H van Deventer
• The role of TNFα and lymphotoxin in demyelinating disease (1 November, 1999)

  Christopher Lock, Jorge Oksenberg, Lawrence Steinman